C57BL/6JCya-Itgalem1flox/Cya
Common Name
Itgal-flox
Product ID
S-CKO-03157
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-16408-Itgal-B6J-VA
Status
When using this mouse strain in a publication, please cite “Itgal-flox Mouse (Catalog S-CKO-03157) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Itgal-flox
Strain ID
CKOCMP-16408-Itgal-B6J-VA
Gene Name
Product ID
S-CKO-03157
Gene Alias
Cd11a, LFA-1, Ly-15, Ly-21, (p180), LFA-1A
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
Chr 7
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000106306
NCBI RefSeq
NM_001253872
Target Region
Exon 5~7
Size of Effective Region
~1.8 kb
Overview of Gene Research
Itgal, also known as Integrin subunit alpha L, encodes an integrin component of LFA-1 and is a membrane receptor molecule widely expressed on leukocytes. It plays a key role in the interaction between white blood cells and other cells, and is involved in immune-related processes [1,2,3,5,6,7,8].
In various cancers, Itgal shows different expression patterns and associations. In non-small-cell lung cancer (NSCLC), its down-regulation in tumor tissues is associated with poor prognosis, and high Itgal expression is related to increased infiltration of CD8+ T cells, CD68+ macrophages, CD4+ T cells, and CD20+ B cells, as well as better outcomes in patients with immune checkpoint inhibitor therapy [1]. In acute myeloid leukemia, high Itgal expression is linked to poor prognosis, and it is associated with age, cytogenetic risk classifications, MDSCs, macrophages, and most immune checkpoint genes and cytokines [2]. In gastric cancer, Itgal expression is increased in cancer samples, related to poor survival, and connected with immunomodulators, chemokines, and infiltrating levels of multiple immune cell types [3]. In melanoma, it is investigated for its relationship with immune infiltration and prognosis [4]. In lung adenocarcinoma, high Itgal expression is an independent predictor of better prognosis, and it suppresses malignant progression [7]. In NSCLC, low Itgal expression is related to poorer prognosis and increased malignancy, and its co-expressed genes are associated with immune-related signaling pathways [8]. In murine low-grade glioma, Itgal/CD11A in glioma-associated microglia is critical for CX3CL1 receptor expression, CX3CL1-directed motility, and glioma mitogen production, and antibody-mediated CD11a inhibition reduces tumor growth in vivo [9].
In conclusion, Itgal is crucial in immune-cell interactions. Studies, especially those using in vivo models like the murine models in low-grade glioma research, have revealed its diverse roles in cancer development, prognosis, and immune-microenvironment regulation, providing potential directions for targeted anti-tumor strategies [9].
References：
1. Zhang, Ruihao, Zhu, Guangsheng, Li, Zaishan, Liu, Hongyu, Chen, Jun. 2024. ITGAL expression in non-small-cell lung cancer tissue and its association with immune infiltrates. In Frontiers in immunology, 15, 1382231. doi:10.3389/fimmu.2024.1382231. https://pubmed.ncbi.nlm.nih.gov/38646528/
2. Li, Ran, Wu, Xiaolu, Xue, Kai, Li, Junmin. 2022. ITGAL infers adverse prognosis and correlates with immunity in acute myeloid leukemia. In Cancer cell international, 22, 268. doi:10.1186/s12935-022-02684-x. https://pubmed.ncbi.nlm.nih.gov/35999614/
3. Zhang, Junchang, Wang, Han, Yuan, Cheng, Zhang, Changhua, He, Yulong. 2022. ITGAL as a Prognostic Biomarker Correlated With Immune Infiltrates in Gastric Cancer. In Frontiers in cell and developmental biology, 10, 808212. doi:10.3389/fcell.2022.808212. https://pubmed.ncbi.nlm.nih.gov/35399517/
4. Deng, TengFei, Wang, Chaoyong, Gao, Cong, Zhang, Qiang, Guo, Jun. 2023. ITGAL as a prognostic biomarker correlated with immune infiltrates in melanoma. In Frontiers in oncology, 13, 1181537. doi:10.3389/fonc.2023.1181537. https://pubmed.ncbi.nlm.nih.gov/37388230/
5. de Lange, Katrina M, Moutsianas, Loukas, Lee, James C, Anderson, Carl A, Barrett, Jeffrey C. 2017. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. In Nature genetics, 49, 256-261. doi:10.1038/ng.3760. https://pubmed.ncbi.nlm.nih.gov/28067908/
6. Lin, Fengjie, Yang, Hanxuan, Huang, Zongwei, Ye, Yunbin, Qiu, Sufang. 2024. Magnesium-related gene ITGAL: a key immunotherapy predictor and prognostic biomarker in pan-cancer. In Frontiers in pharmacology, 15, 1464830. doi:10.3389/fphar.2024.1464830. https://pubmed.ncbi.nlm.nih.gov/39605903/
7. Xiao, Zengtuan, Nian, Zhe, Zhang, Mengzhe, Liu, Zhe, Zhang, Zhenfa. . Integrated analysis highlights the significance role of ITGAL in lung adenocarcinoma. In Journal of cellular and molecular medicine, 28, e18289. doi:10.1111/jcmm.18289. https://pubmed.ncbi.nlm.nih.gov/38613346/
8. Wang, Qiang, Xiao, GuangJun, Li, Na, Jiang, Xiulin, Li, Chunhong. 2023. lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma. In Aging, 15, 4510-4523. doi:10.18632/aging.204756. https://pubmed.ncbi.nlm.nih.gov/37256932/
9. De Andrade Costa, Amanda, Chatterjee, Jit, Cobb, Olivia, Dahiya, Sonika, Gutmann, David H. . RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth. In Neuro-oncology, 24, 14-26. doi:10.1093/neuonc/noab130. https://pubmed.ncbi.nlm.nih.gov/34043012/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.